Open Trial of Trauma-Focused Psychodynamic Psychotherapy for Posttraumatic Stress Disorder Among LGBTQ Individuals
Publication: American Journal of Psychotherapy
Abstract
Objective:
Lesbian, gay, bisexual, transgender, and queer (LGBTQ) individuals report higher rates of exposure to traumatic events and posttraumatic stress disorder (PTSD) compared with heterosexual and cisgender individuals. No treatment outcomes research has focused on PTSD in the LGBTQ population. Trauma-focused psychodynamic psychotherapy (TFPP) is a brief, manualized, attachment- and affect-focused psychotherapy for PTSD. TFPP explicitly incorporates broad identity-related and societal factors into its conceptualization of trauma and its consequences, which may be especially helpful for LGBTQ patients with minority stress who seek affirmative care.
Methods:
Fourteen LGBTQ patients with PTSD, assessed with the Clinician-Administered PTSD Scale for DSM-5 (CAPS-5), received 24 sessions of twice-weekly (12 weeks) TFPP via teletherapy provided by supervised early-career therapists inexperienced in the modality. Sessions were videotaped to monitor therapists’ treatment adherence. Patients were assessed at baseline, week 5, termination (week 12), and 3 months posttreatment for PTSD symptoms (assessed with the CAPS-5) and secondary outcomes.
Results:
TFPP was well tolerated by patients, with 12 (86%) completing the intervention. CAPS-5–measured PTSD symptoms, including dissociation, significantly improved during treatment (mean decrease=−21.8, d=−1.98), and treatment gains were maintained at follow-up. Most patients experienced PTSD clinical response (N=10, 71%) or diagnostic remission (N=7, 50%). Patients generally experienced significant, concomitant improvements in complex PTSD symptoms, general anxiety, depression, and psychosocial functioning. Adherence to the intervention among therapists was high, with 93% of rated sessions meeting adherence standards.
Conclusions:
TFPP shows promise in the treatment of PTSD among sexual and gender minority patients seeking LGBTQ-affirmative PTSD care.
HIGHLIGHTS
•
Lesbian, gay, bisexual, transgender, and queer (LGBTQ) individuals are at heightened risk for developing posttraumatic stress disorder (PTSD) compared with heterosexual and cisgender individuals.
•
Among LGBTQ patients with PTSD, trauma-focused psychodynamic psychotherapy (TFPP) was associated with a high rate of PTSD clinical response (71%), which was maintained at 3-month follow-up.
•
TFPP was also well tolerated (86% completed the intervention) and was associated with improvements in complex PTSD symptoms, general anxiety, depression, and psychosocial functioning.
•
TFPP shows promise as an affect- and attachment-focused psychotherapy for treating PTSD among LGBTQ individuals.
Lesbian, gay, bisexual (1–3), and transgender (4–6) individuals report higher rates of exposure to physical and sexual abuse as children and to physical and sexual assault as adults relative to heterosexual and cisgender individuals. Perhaps consequently, posttraumatic stress disorder (PTSD) disproportionately affects people who identify as lesbian, gay, bisexual, transgender, or queer (LGBTQ). In the National Epidemiologic Survey on Alcohol and Related Conditions, participants identifying as gay or bisexual exhibited a PTSD prevalence twice that of heterosexual participants (7). No comparable epidemiological data have been published on PTSD rates among transgender individuals; however, the rate of PTSD diagnosis in the U.S. Department of Veterans Affairs (VA) health care system, as recorded in electronic medical records, is approximately 50% higher among transgender than among cisgender veterans (8).
Some LGBTQ patients with PTSD report impactful experiences of minority stress (9), such as discrimination or stigmatization, or identify DSM-5 PTSD criterion A traumas involving LGBTQ identity (e.g., gay bashing), which may influence how PTSD symptoms manifest or may trigger episodes (10–15). Minority stress may also aggravate other risk factors for developing PTSD, such as a less secure attachment style (11, 16–18). LGBTQ individuals are also relatively more likely than heterosexual or cisgender individuals to experience material stressors and interpersonal losses, such as losing housing or experiencing parental or community rejection, which can hinder adaptation to traumatic events (1, 19).
Despite high rates of trauma exposure and PTSD diagnosis, the efficacy of therapies specifically for PTSD has not been examined for the LGBTQ population (20). Research on the effects and tolerability of PTSD therapies among LGBTQ patients is critical given the outsized impact of PTSD and the need for PTSD treatment in this population. For example, at a free LGBTQ-oriented mental health clinic at a teaching hospital in New York City, 65% of patients seeking treatment over a 2-year period reported having a potential PTSD diagnosis, in accordance with a recommended cutoff score on the PTSD Symptom Checklist for DSM-IV (21). Some LGBTQ patients with PTSD may benefit from therapists who explicitly consider the role of identity factors or other potentially important and preoccupying developmental (e.g., family rejection, alienation) or contemporary experiences (e.g., internalized stigma) beyond the index trauma (22). Application of trauma-focused therapy techniques may also require additional sensitivity toward the contexts and realities of different LGBTQ patients. For example, in vivo exposure exercises in prolonged exposure (PE) therapy may need to be adapted to the needs of some individuals in order to realistically titrate exposure to environments and situations in which they are at genuine heightened risk for anti-LGBTQ discrimination or violence (12).
Trauma-focused cognitive-behavioral therapies (CBTs) such as PE therapy and cognitive processing therapy, often considered mainstay evidence-based treatments for PTSD, can be effective (23) but are often associated with high dropout rates (30%–50%) and incomplete clinical response (approximately 50% among those who complete treatment) (24, 25). In clinical trials, exposure-focused treatments have been shown to have higher dropout rates among African Americans (26, 27) and individuals with extensive experiences of childhood abuse (26, 28) relative to their peers, which may limit the reach of these therapies among polytraumatized LGBTQ patients with intersectional minority identities. Establishing the efficacy of alternative therapeutic modalities for PTSD will likely be critical to lessening the outsized burden of PTSD in the LGBTQ population because no single therapy or primary therapeutic focus (e.g., structured, repeated exposure to trauma memories) will be effective or tolerable for all patients.
To address these specific treatment needs, we conducted an open trial of trauma-focused psychodynamic psychotherapy (TFPP), an affect- and attachment-focused psychotherapy (29), to treat PTSD among LGBTQ patients. TFPP was adapted from panic-focused psychodynamic psychotherapy (30), the only empirically supported, efficacious non–exposure-focused psychodynamic therapy for panic disorder and other anxiety disorders (31–33). One aim of TFPP is to improve patients’ ability to tolerate, understand, and manage intense emotions that suddenly and unpredictably appear, a phenomenon related to patients’ tendency to reexperience traumatic events in the here and now, unexpectedly and when danger is not present. TFPP engages the psychological meanings of symptoms and their relationship to traumatic events to help patients better understand the emotional underpinnings of symptom triggers and to untangle ways in which emotional meanings of trauma affect current experiences. TFPP is used to help patients elucidate, tolerate, and work through intrapsychic conflicts potentially contributing to PTSD symptoms, such as the difficulty patients often have in experiencing or expressing anger, which may be linked in an individual’s mind to traumatic experiences (e.g., as an identification with one’s abuser). TFPP was developed with patients with complex PTSD in mind; these individuals often have multiple prior traumas with no clear index trauma (34). TFPP incorporates opportunities for patients to explore, within a psychodynamic developmental framework, the broader context of their symptoms and difficulties in their lives, including but not limited to LGBTQ identity and minority stress (29). In this study, TFPP was delivered by teletherapy to 14 LGBTQ patients with PTSD during the COVID-19 pandemic.
Methods
Patients
No deviations from the registered trial protocol were made. All screening, assessment, and psychotherapy for the study took place over a secure teletherapy platform. Patients provided informed written consent for participation, and the protocol was approved by the Weill Cornell Medical College Institutional Review Board. Inclusion criteria were a diagnosis of PTSD in accordance with the Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) (35), identifying as LGBTQ (i.e., as a sexual or gender minority individual), having stable psychiatric medications for the past 2 months and agreeing to remain on a stable dose or combination during the study treatment, and being ages 18–65. Exclusion criteria were psychosis; bipolar I disorder; severe suicidality (e.g., patients demonstrating suicidal intent or plan); primary substance use disorder; severe major depressive disorder, defined as a score ≥24 on the 17-item Hamilton Rating Scale for Depression (HRSD) (36); and neurocognitive or developmental disorders likely to interfere substantially with participating in study procedures and psychotherapy.
Patients were seeking treatment and were referred to the study via Weill Cornell Medical College, advertisements on Facebook and Instagram, self-referral, or community referral. Patients were administered a telephone screening for presence of PTSD and absence of major exclusion criteria before being invited to complete a more thorough assessment. The Structured Clinical Interview for DSM-5 (37) was administered to thoroughly determine the presence of symptoms related to comorbid conditions and exclusion criteria.
Twenty-seven patients were screened, 21 were offered an intake assessment interview, and 14 completed the assessment and were invited to begin treatment. (A CONSORT diagram and additional details on the study’s design and methods [e.g., therapist training, adherence] are available in the online supplement to this article.)
Trauma-Focused Psychodynamic Psychotherapy
TFPP is a manualized, brief, 24-session, twice-weekly psychodynamic therapy developed specifically for the treatment of PTSD (29). TFPP focuses on how trauma disrupts attachment (17, 38) and the capacity for mentalization and symbolization (39) and on intrapsychic, trauma-related conflicts, all of which can lead to unsuccessful attempts to avoid engaging with the psychological meanings or the impact of traumatic experiences that lead to symptoms. Psychodynamic interventions such as clarification, confrontation, and interpretation help patients improve reflective functioning regarding the psychological meanings and contexts of symptoms, reduce dissociation and affective numbing (40), identify and work through traumatic repetitions and intrapsychic conflicts, and develop better narrative coherence regarding their trauma and life history. The therapist attends to and addresses transference as an important arena for exploring trauma-related dynamics, which commonly include conflicts related to trust, fear of dependency, and expression of anger. Importantly, PTSD symptoms are used as a lens through which to understand underlying meanings and dynamics. The therapist may tactfully and carefully solicit details about emotionally relevant aspects of the traumatic event or may focus on elements of the event that evoke high degrees of conflict (e.g., gaps in memory, confusions) in the service of not modeling avoidance of trauma-related memories or their meanings (41). However, no structured exposure exercises or in-session discussions about the details of a patient’s trauma are required, and no homework is assigned.
Factors related to LGBTQ identity and minority stress were conceptualized within TFPP’s framework to incorporate systemic and cultural influences on patients’ experiences and patients’ adaptation to traumatic events into the treatment approach. For example, this model considers how the impact of traumas experienced as an adult may be amplified and overlaid by past experiences of oppression or discrimination (Figure 1). Although therapists followed the American Psychological Association’s recommendations for LGBTQ-affirmative psychotherapy (42), per TFPP’s nondirective psychodynamic model, therapists did not set an a priori agenda to discuss LGBTQ-related topics. Rather, therapists were guided to be attentive to potential avoidance of and conflicts related to discussing LGBTQ identity and to actively address these issues. Therapists were encouraged to explore connections between PTSD symptoms and both identity-related information and the therapeutic process (e.g., anxiously experiencing the therapist as a potential oppressor, experiencing PTSD intrusions during sex) as they emerged during sessions. All treatments were delivered over a secure teletherapy platform (video and audio) because the study occurred during the height of the COVID-19 pandemic in the United States (September 2020–June 2021).
Therapists
Seven psychotherapists delivered TFPP: one Ph.D clinical psychology intern, one M.D. psychiatry resident, three Ph.D. psychology postdoctoral fellows, one M.D. psychiatry psychotherapy fellow, and one early-career M.D. psychiatrist. All but one therapist was new to delivery of TFPP, only two therapists had ever delivered a manualized psychodynamic therapy, and two therapists had never delivered a psychodynamic therapy. Therapists had an average of 1 year of postdoctoral experience. Six therapists were cisgender women, and one was a cisgender man. All therapists participated in a 1.5-day training program and attended weekly group supervision.
Therapists were supervised weekly for 1 hour in groups of three to four. Supervision was led by the TFPP developer (B.L.M.), and therapists were cosupervised by the primary study author (J.R.K.). Therapists presented case material, including videotaped sessions, to the supervision group. TFPP adherence ratings were made for 15 randomly selected taped sessions, and raters (B.L.M., J.R.K.) used the standardized TFPP adherence measure (available on request; see online supplement ). In this study, 93% (N=14 of 15) of rated sessions met adherence standards (score ≥4 on at least five of seven items; score range 0–6, with higher scores indicating greater adherence).
Measures
All observer-reported measures were delivered by two independent clinical assessors (C.L., A.M.), medical students volunteering at the Weill Cornell LGBTQ Wellness Qlinic, who were uninformed about specific study hypotheses. Assessors were trained and supervised by a licensed clinical psychologist (J.R.K.). Patients were compensated only for participating in study assessments ($50 for baseline assessment, $30 for each subsequent assessment), not for attending therapy sessions. Psychotherapy was provided gratis.
Primary Outcome
The CAPS-5 is the best-established observer-based interview measure for diagnosis and assessment of PTSD on the basis of DSM-5 criteria (35). Individual items reflecting DSM-5 criteria are scored from 0 to 4 by using a structured guide, where higher scores reflect more severe symptoms and scores ≥2 reflect a clinically significant symptom that contributes to making a PTSD diagnosis. The CAPS-5 total score was our primary study outcome. Patients were assessed at baseline, week 5, termination (week 12), and 3 months posttreatment. Clinical response on the CAPS-5 was defined a priori as a 30% reduction from baseline CAPS-5 total score (43). The “last observation carried forward” strategy was applied to patients who did not complete the trial, exclusively for the metric of clinical response. We also analyzed change in symptoms of dissociation (measured by two items) among individuals reporting dissociation at baseline. Ten videorecorded assessment tapes were double-rated and analyzed for interrater reliability (total CAPS-5 score: intraclass correlation coefficient [model 2,1]=0.91; presence of CAPS-5 PTSD diagnosis: κ=1.00).
Secondary Outcomes
Complex PTSD symptoms.
The International Trauma Interview (ITI) developed by the ICD-11 complex PTSD working group was used to assess complex PTSD symptoms (44). Meeting at least one criterion each (score ≥2) from the affective dysregulation, identity, and interpersonal domains of the measure indicated a diagnosis of complex PTSD per ICD-11 criteria. The ITI was collected at all time points.
Depression and anxiety.
The HRSD (36) and Hamilton Anxiety Rating Scale (HARS) (45), well-established semistructured interviews to assess general mood and anxiety symptoms, were collected pre- and posttreatment (termination). We used the reconstructed versions to more specifically differentiate general anxiety from depression symptoms (46).
Psychosocial impairment.
The Sheehan Disability Scale (SDS) is a self-report measure that assesses the degree to which psychiatric symptoms interfere with the ability to function in work, social, and family roles (47). The SDS was administered at baseline, week 5, and treatment termination.
Statistical Analysis
All available data for patients were analyzed by using an intention-to-treat method. Change in clinical measures during the study was analyzed in a linear mixed model by using the R packages lme4 (48) and lmerTest (49). An a priori power analysis was calculated for a mixed-model analysis of CAPS-5 score change, aiming to detect a large effect size (α=0.05, 99% power, three measurements, repeated-measures r=0.50, Cohen’s d=1.00) commensurate with within-groups CAPS-5 effects for efficacious PTSD psychotherapies (43, 50) for a target sample of N=15.
For the primary outcome (CAPS-5) and all outcomes collected at three time points, a two-level mixed-model structure was set, with a random effect of slope (level 2) nested in a random person-level intercept (level 1). Time was modeled as a linear effect of assessment (0, 1, 2), and a significant fixed effect of time reflected reliable change in that measure during treatment. For outcomes assessed at only two time points (reconstructed HRSD and HARS), no random slope was specified because models could not converge in this small sample. Beta weights for reported tests reflect estimates of slopes of change, and Cohen’s d was also provided to describe the magnitude of average within-person change on a given outcome measure.
Results
Baseline Characteristics
Patients’ baseline characteristics (N=14) are reported in Table 1. A majority of patients (N=11, 79%) identified a sexual assault as an adult or sexual abuse as a child or adolescent as their criterion A trauma to anchor the CAPS-5 interview. Of note, the sample was not treatment-naïve; patients reported an average of 1.6 prior psychotherapies focused on treating their PTSD, and, on entering the trial, most patients (N=11, 79%) were actively taking psychiatric medications, which were held constant throughout the trial.
| Characteristic | N | % |
|---|---|---|
| Age (M±SD years) | 37.2±10.2 | |
| Gender | ||
| Cisgender female | 10 | 71 |
| Cisgender male | 1 | 7 |
| Transgender female | 1 | 7 |
| Gender nonbinary | 2 | 14 |
| Sexual orientation | ||
| Homosexual | 9 | 64 |
| Bisexual, pansexual | 5 | 36 |
| Race | ||
| Caucasian | 10 | 71 |
| Black | 3 | 21 |
| Asian | 1 | 7 |
| Ethnicity | ||
| Hispanic or Latinx | 1 | 7 |
| Not Hispanic or Latinx | 13 | 93 |
| Relationship status | ||
| Single | 5 | 36 |
| Cohabiting, partnered | 9 | 64 |
| Employment | ||
| Full-time employment | 6 | 43 |
| Part-time employment | 2 | 14 |
| Full- or part-time student | 4 | 29 |
| Unemployed | 2 | 14 |
| Education | ||
| High school | 3 | 21 |
| Associate’s degree | 1 | 7 |
| Bachelor’s degree | 6 | 43 |
| Master’s degree or higher | 4 | 29 |
| Medical insurance | ||
| Public (Medicaid) | 9 | 64 |
| Private | 4 | 29 |
| No insurance | 1 | 7 |
| N of past therapies for PTSD (M±SD) | 1.6±1.1 | |
| Past suicide attempt | 1 | 7 |
| Psychotropic medications (any)b | 11 | 79 |
| SSRI or SNRI | 7 | 50 |
| Benzodiazepines | 3 | 21 |
| Second-generation antipsychotics | 2 | 14 |
| Bupropion | 2 | 14 |
| N of medications (M±SD) | 1.2±1.0 | |
| Current N of comorbid conditions (M±SD)b,c | 1.8±1.3 | |
| Major depressive disorder | 6 | 43 |
| Persistent depressive disorder | 1 | 7 |
| Generalized anxiety disorder | 6 | 43 |
| Panic disorder | 5 | 36 |
| Agoraphobia | 2 | 14 |
| Social anxiety disorder | 2 | 14 |
| Separation anxiety disorder | 5 | 36 |
| CAPS-5 criterion A trauma | ||
| Sexual assault as adult | 8 | 57 |
| Sexual abuse as child or adolescent | 3 | 21 |
| Physical abuse as child or adolescent | 2 | 14 |
| Witnessed serious accident | 1 | 7 |
| LEC-5 itemb | ||
| Natural disaster | 7 | 50 |
| Fire or explosion | 1 | 7 |
| Transportation accident | 9 | 64 |
| Serious accident | 5 | 36 |
| Physical assault | 11 | 79 |
| Assault with weapon | 5 | 36 |
| Sexual assault | 10 | 71 |
| Other unwanted or uncomfortable sexual experience | 12 | 86 |
| Captivity | 4 | 29 |
| Life-threatening illness or injury | 6 | 43 |
| Severe human suffering | 5 | 36 |
| Witnessed sudden violent death | 3 | 21 |
| Witnessed sudden accidental death | 3 | 21 |
| Witnessed other serious injury or death | 1 | 7 |
| Other potentially traumatic events | 9 | 64 |
| Childhood Trauma Questionnaire score (M±SD)d | 2.6±.7 | |
| Reported duration of PTSD (M±SD months) | 59.4±61.9 | |
| ICD-11 complex PTSD diagnosis | 6 | 43 |
| SCID-II borderline personality disorder criteria (M±SD)e | .6±1.3 |
a
CAPS-5, Clinician-Administered PTSD Scale for DSM-5; LEC-5, Life Events Checklist for DSM-5; LGBTQ, lesbian, gay, bisexual, transgender, and queer; SCID-II, Structured Clinical Interview for DSM-IV Axis II Personality Disorders; SNRI, serotonin and norepinephrine reuptake inhibitor; SSRI, selective serotonin reuptake inhibitor.
b
Participants could select more than one subcategory.
c
All comorbid conditions assessed with DSM-5 were determined by using the Structured Clinical Interview for DSM-5, except for separation anxiety, which was diagnosed via the Structured Clinical Interview for Separation Anxiety Symptoms.
d
Scores reflect the average of individual items (range 1–5), with higher scores indicating more severe maltreatment.
e
SCID-II criteria for borderline personality disorder range from 0 to 1 (diagnostic criteria present versus absent).
Treatment Retention and Adverse Events
Two patients (14%) dropped out of treatment, both during week 5: one patient dropped out after completing their midpoint assessment at session 10 because they did not find the therapy to be helpful, and one patient dropped out after session 9 because of significant difficulties meeting study demands (e.g., attending therapy sessions). All other patients completed all 24 sessions of TFPP.
No study-related adverse events were documented. One patient had a medical event (myocardial infarction) requiring hospitalization and paused study-related treatment for 2 weeks; this patient completed therapy.
Primary Outcome
Termination.
Of 14 patients included in statistical analyses, 10 (71%) met criteria for clinical response (improvement of ≥30% in CAPS-5 total score from baseline to termination). CAPS-5 PTSD symptoms significantly improved during treatment (mean decrease=−21.8, d=−1.98). Seven (50%) patients also no longer met DSM-5 diagnostic criteria for PTSD. On average, patients exhibited a significant improvement in CAPS-5 scores across the three assessments (β=−10.8, 95% CI=−16.3 to −6.0, t=−4.42, df=5.7, p=0.005, d=−1.98). The breakdown of clinical outcomes by PTSD symptom cluster is presented in Table 2. Among patients who reported symptoms of dissociation on the CAPS-5 at baseline (N=6, 43%), improvement in dissociation occurred (β=−1.5, 95% CI=−2.6 to −0.6, t=−3.20, df=3.2, p=0.030).
| M±SD | Cohen’s d | |||||
|---|---|---|---|---|---|---|
| Outcome measure | Baseline (N=14) | Week 5, session 10 (N=13) | Termination (N=12) | 3-month follow-up (N=11) | Baseline to termination | Baseline to 3-month follow-up |
| CAPS-5 scoreb | 39.3±11.8 | 27.3±12.3 | 17.5±10.2 | 13.9±9.4 | −1.98 | −2.38 |
| Intrusion | 11.1±3.9 | 6.9±2.9 | 3.8±3.2 | 3.0±3.0 | −2.05 | −2.32 |
| Avoidance | 5.0±1.9 | 2.9±1.9 | .8±1.5 | 1.8±1.9 | −2.45 | −1.68 |
| Cognitive/affective | 12.9±5.1 | 10.1±5.6 | 7.6±6.2 | 5.8±5.3 | −.93 | −1.37 |
| Hyperarousal | 10.3±2.9 | 7.4±3.1 | 5.4±3.4 | 3.4±2.4 | −1.55 | −2.59 |
| ITIc | 8.3±5.3 | 7.6±5.4 | 5.0±5.2 | 4.1±5.8 | −.63 | −.88 |
| HRSDd | 14.8±9.0 | 7.3±8.0 | −.88 | |||
| HARSe | 15.4±8.1 | 8.4±7.7 | −.89 | |||
| SDSf | 18.4±8.2 | 16.7±7.2 | 10.2±7.8 | −1.02 | ||
a
Effect sizes were calculated by using the standard formula for Cohen’s d: [(mean 2 – mean 1) ÷ pooled standard deviation]. LGBTQ, lesbian, gay, bisexual, transgender, and queer.
b
Scores on the Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) range from 0 to 80, with higher scores indicating more severe PTSD symptoms. Subscale ranges: intrusion, 0–20; avoidance, 0–8; cognitive/affective, 0–28; hyperarousal, 0–24.
c
Scores on the International Trauma Interview for ICD-11 complex PTSD diagnosis (ITI) range from 0 to 24, with higher scores indicating worse symptoms.
d
Scores on the reconstructed Hamilton Rating Scale for Depression (HRSD) range from 0 to 50, with higher scores indicating more depression symptoms.
e
Scores on the reconstructed Hamilton Anxiety Rating Scale (HARS) range from 0 to 60, with higher scores indicating greater anxiety.
f
Scores on the Sheehan Disability Scale (SDS) range from 0 to 30, with higher scores indicating greater dysfunction.
Follow-up.
Eleven patients were assessed at the 3-month posttreatment follow-up. The two patients who dropped out of the study and one patient who completed treatment were not reachable at follow-up. One patient who did not show clinical response at study termination attained response by the 3-month follow-up. Ninety-one percent (N=10 of 11) of patients assessed at follow-up, or 71% (N=10 of 14) of the total sample, met criteria for clinical response, counting patients not assessed at follow-up as nonresponders. We found no evidence of symptom recurrence between termination and the 3-month follow-up, and patients generally experienced a small improvement in symptoms between these time points (β=−3.6, 95% CI=−6.5 to −0.8, t=−2.64, df=7.0, p=0.034). No patients reported seeing a therapist outside the study or a change in psychiatric medication during the 3 months following termination, and only two patients who completed therapy attended an available booster session during the follow-up interval.
Secondary Outcomes
ICD-11–defined symptoms of complex PTSD, as measured by the ITI, significantly improved during treatment (β=−3.3, 95% CI=−5.8 to −0.8, t=−2.7, df=8.5, p=0.024, d=−0.63), with the bulk of improvement occurring in the second half of treatment (Table 2). Both anxiety (β=−6.1, 95% CI=−9.7 to −2.8, t=−3.7, df=7.4, p=0.007, d=−0.89) and depression (β=−8.6, 95% CI=−13.4 to −3.5, t=−3.6, df=7.8, p=0.008, d=−0.88) improved significantly over the course of treatment, as measured by the reconstructed HARS and HRSD, respectively. Psychosocial impairment on the SDS also improved significantly (β=−3.9, 95% CI=−6.7 to −1.1, t=−2.76, df=16.0, p=0.014, d=−1.02).
Discussion
This study demonstrates that LGBTQ patients with a primary diagnosis of PTSD who received 24 sessions of TFPP experienced significant improvement in PTSD symptoms during treatment, with a high rate of clinical response (71%) that was maintained at the 3-month follow-up. The cohort of LGBTQ patients in this study had typically experienced sexual assault; reported severe, chronic (mean duration=59.4 months) PTSD symptoms on the CAPS-5; and had a high rate of complex PTSD (43%) as defined by the ICD-11. TFPP was well tolerated, with 12 (86%) patients completing all therapy sessions. These high rates of treatment completion and clinical response are promising; nearly all patients had attempted at least one PTSD-focused therapy that was not effective in achieving PTSD remission before entering the study, and dropout rates in trauma-focused PTSD therapies can be high, estimated at 42% in a recent meta-analysis (51). Patients experienced improvements in symptoms of complex PTSD (e.g., affective numbing), depression, general anxiety, and psychosocial functioning. These findings provide further evidence that therapies that do not focus on therapist-guided exposure to trauma memories (e.g., interpersonal psychotherapy [IPT]) may be effective in treating PTSD (43, 50).
In this trial, therapists used an LGBTQ-affirming approach to treatment (42) and aimed to flexibly integrate LGBTQ identity and minority stress into TFPP case conceptualization and the therapeutic process. This approach may partially account for TFPP’s achievement of high rates of clinical response and treatment completion; psychotherapies that are culturally adapted to specific groups tend to demonstrate advantages of small to medium effect sizes compared with unmodified treatments (52). In further qualitative research with data from interviews at study termination, we will assess the impact of both general and LGBTQ-specific therapy process factors identified by patients. On the basis of the supervisory principles and qualitative findings from this trial, we are preparing additional research studies concerning treatment of identity-related trauma within a TFPP or psychodynamic framework (e.g., attending to transference informed by identity-based discrimination or oppression).
Some patients may have responded preferentially to the specific therapeutic frame, focus, and interventions of TFPP. In contrast to trauma-focused CBTs, TFPP is intended to address how PTSD can disrupt the capacity to reflect on and make sense of both internal experiences and the minds of others (i.e., mentalization) (39, 53), particularly in regard to trauma-related conflicts, and to address the often profound disturbances in attachment and interpersonal relatedness that can be sequelae of trauma (17, 38, 54). TFPP’s exploratory, interpretive interventions are used to help patients engage their capacity to reflect on and integrate dissociated affects and psychological meanings and to address unconscious conflicts, fantasies, and repetitions contributing to PTSD symptoms. Each family of PTSD therapies may be more helpful, on average, for specific types of patients than for others, and randomized comparisons with other treatment interventions can help reveal which patients may particularly benefit from TFPP relative to other efficacious therapies (26). For example, in a separate clinical trial for PTSD, patients identifying sexual trauma as their criterion A PTSD anchor were found to have superior PTSD outcomes with IPT, another attachment- and affect-focused psychotherapy, compared with PE therapy (55).
Finally, early-career therapists who delivered TFPP generally achieved high treatment adherence. This is noteworthy because most study therapists had not previously delivered TFPP, and two were entirely new to delivering psychodynamic therapies.
This study had several limitations. Although the observed treatment retention and clinical response rates are encouraging, this study was a small (N=14) open trial, which can have a bias toward positive results (56). To test the efficacy of TFPP, further study is required among LGBTQ individuals in a randomized comparison against another intervention for PTSD, likely PE therapy. We are also testing TFPP compared with treatment as usual in an ongoing randomized controlled trial among veterans with PTSD who did not respond to or dropped out of PE therapy or cognitive processing therapy at three VA hospitals in New York City (ClinicalTrials.gov: NCT03755401).
The therapeutic processes most associated with therapeutic change in TFPP are unknown. In panic-focused psychodynamic psychotherapy, the treatment from which TFPP was adapted, a greater focus both on the therapist’s interpretation of dynamics surrounding symptoms (57) and on in-session patient emotional expression (58) predicted greater subsequent improvements in panic symptoms and development of symptom-specific reflective functioning, which mediate symptom relief (59). We also did not assess LGBTQ-related minority stress and its impacts over the course of therapy, which may have helped to elucidate the extent to which TFPP successfully addressed these factors and whether better adaptation to minority stress also helped relieve PTSD symptoms (60).
Although our cohort was socioeconomically diverse (64% [N=9] were low-income patients on Medicaid), diversity was not reflected in the racial-ethnic composition of our sample, with only four patients identifying as persons of color. Furthermore, only one patient identifying as male participated in the therapy. Gathering more data on the utility of TFPP for gender minority (e.g., transgender) patients will be essential (15).
Conclusions
TFPP is an affect- and attachment-focused psychodynamic psychotherapy that can potentially address aspects of PTSD that differ from those addressed by trauma-focused CBTs and shows promise as an effective treatment among LGBTQ patients with PTSD.
Acknowledgments
The authors thank the therapists involved in the study for volunteering their time and effort to treat participating patients: Robin Brody, Psy.D., Alyson Gorun, M.D., Rebecca Klein, M.D., Jessica Kovler, Ph.D., and Kibby McMahon, Ph.D. The authors also thank the patients in this study for their time and effort participating in research assessments and the study intervention and Marylene Cloitre, Ph.D., and Neil Roberts, Ph.D., for sharing the International Trauma Interview for complex posttraumatic stress disorder symptoms before its general dissemination. Finally, the authors thank Chloe Roske, B.A., for her support in preparing revisions of the manuscript.
Footnote
This trial was registered at ClinicalTrials.gov: NCT04532996.
Supplementary Material
File (appi.psychotherapy.20220037.ds001.pdf)
- View/Download
- 367.17 KB
References
1.
McLaughlin KA, Hatzenbuehler ML, Xuan Z, et al: Disproportionate exposure to early-life adversity and sexual orientation disparities in psychiatric morbidity. Child Abuse Negl 2012; 36:645–655
2.
Balsam KF, Rothblum ED, Beauchaine TP: Victimization over the life span: a comparison of lesbian, gay, bisexual, and heterosexual siblings. J Consult Clin Psychol 2005; 73:477–487
3.
Zou C, Andersen JP: Comparing the rates of early childhood victimization across sexual orientations: heterosexual, lesbian, gay, bisexual, and mostly heterosexual. PLoS One 2015; 10:e0139198
4.
Langenderfer-Magruder L, Whitfield DL, Walls NE, et al: Experiences of intimate partner violence and subsequent police reporting among lesbian, gay, bisexual, transgender, and queer adults in Colorado: comparing rates of cisgender and transgender victimization. J Interpers Violence 2016; 31:855–871
5.
Lefevor GT, Boyd-Rogers CC, Sprague BM, et al: Health disparities between genderqueer, transgender, and cisgender individuals: an extension of minority stress theory. J Couns Psychol 2019; 66:385–395
6.
Shipherd JC, Maguen S, Skidmore WC, et al: Potentially traumatic events in a transgender sample: frequency and associated symptoms. Traumatology 2011; 17:56–67
7.
Rodriguez-Seijas C, Eaton NR, Pachankis JE: Prevalence of psychiatric disorders at the intersection of race and sexual orientation: results from the National Epidemiologic Survey of Alcohol and Related Conditions–III. J Consult Clin Psychol 2019; 87:321–331
8.
Livingston NA, Lynch KE, Hinds Z, et al: Identifying posttraumatic stress disorder and disparity among transgender veterans using nationwide Veterans Health Administration electronic health record data. LGBT Health 2022; 9:94–102
9.
Meyer IH: Prejudice, social stress, and mental health in lesbian, gay, and bisexual populations: conceptual issues and research evidence. Psychol Bull 2003; 129:674–697
10.
Livingston NA, Berke DS, Ruben MA, et al: Experiences of trauma, discrimination, microaggressions, and minority stress among trauma-exposed LGBT veterans: unexpected findings and unresolved service gaps. Psychol Trauma 2019; 11:695–703
11.
Keating L, Muller RT: LGBTQ+ based discrimination is associated with PTSD symptoms, dissociation, emotion dysregulation, and attachment insecurity among LGBTQ+ adults who have experienced trauma. J Trauma Dissociation 2020; 21:124–141
12.
Livingston NA, Berke D, Scholl J, et al: Addressing diversity in PTSD treatment: clinical considerations and guidance for the treatment of PTSD in LGBTQ populations. Curr Treat Options Psychiatry 2020; 7:53–69
13.
Reisner SL, White Hughto JM, Gamarel KE, et al: Discriminatory experiences associated with posttraumatic stress disorder symptoms among transgender adults. J Couns Psychol 2016; 63:509–519
14.
Robinson JL, Rubin LJ: Homonegative microaggressions and posttraumatic stress symptoms. J Gay Lesbian Ment Health 2016; 20:57–69
15.
Barr SM, Snyder KE, Adelson JL, et al: Posttraumatic stress in the trans community: the roles of anti-transgender bias, non-affirmation, and internalized transphobia. Psychol Sex Orientat Gend Divers 2022; 9:410–421
16.
Zakalik RA, Wei M: Adult attachment, perceived discrimination based on sexual orientation, and depression in gay males: examining the mediation and moderation effects. J Couns Psychol 2006; 53:302–313
17.
Woodhouse S, Ayers S, Field AP: The relationship between adult attachment style and post-traumatic stress symptoms: a meta-analysis. J Anxiety Disord 2015; 35:103–117
18.
Silove D, Alonso J, Bromet E, et al: Pediatric-onset and adult-onset separation anxiety disorder across countries in the World Mental Health Survey. Am J Psychiatry 2015; 172:647–656
19.
Austin A, Herrick H, Proescholdbell S: Adverse childhood experiences related to poor adult health among lesbian, gay, and bisexual individuals. Am J Public Health 2016; 106:314–320
20.
Pachankis JE: The scientific pursuit of sexual and gender minority mental health treatments: toward evidence-based affirmative practice. Am Psychol 2018; 73:1207–1219
21.
Zhou C, Fruitman K, Szwed S, et al: Weill Cornell Medicine Wellness Qlinic: adapting the student-run clinic model to expand mental health services and medical education. Community Ment Health J 2022; 58:1244–1251
22.
Pachankis JE, Soulliard ZA, Morris F, et al: A model for adapting evidence-based interventions to be LGBQ-affirmative: putting minority stress principles and case conceptualization into clinical research and practice. Cogn Behav Pract 2023; 30:1–17
23.
Cusack K, Jonas DE, Forneris CA, et al: Psychological treatments for adults with posttraumatic stress disorder: a systematic review and meta-analysis. Clin Psychol Rev 2016; 43:128–141
24.
Kehle-Forbes SM, Meis LA, Spoont MR, et al: Treatment initiation and dropout from prolonged exposure and cognitive processing therapy in a VA outpatient clinic. Psychol Trauma 2016; 8:107–114
25.
Steenkamp MM, Litz BT, Marmar CR: First-line psychotherapies for military-related PTSD. JAMA 2020; 323:656–657
26.
Keefe JR, Wiltsey Stirman S, Cohen ZD, et al: In rape trauma PTSD, patient characteristics indicate which trauma-focused treatment they are most likely to complete. Depress Anxiety 2018; 35:330–338
27.
Lester K, Resick PA, Artz C, et al: Impact of race on early treatment termination and outcomes in posttraumatic stress disorder treatment. J Consult Clin Psychol 2010; 78:480–489
28.
Cloitre M, Stovall-McClough KC, Nooner K, et al: Treatment for PTSD related to childhood abuse: a randomized controlled trial. Am J Psychiatry 2010; 167:915–924
29.
Busch FN, Milrod BL, Chen CK, et al: Trauma-Focused Psychodynamic Psychotherapy: A Step-by-Step Treatment Manual. New York, Oxford University Press, 2021
30.
Busch FN, Milrod BL, Singer MB, et al: Manual of Panic Focused Psychodynamic Psychotherapy—eXtended Range. New York, Routledge, 2012
31.
Keefe JR, Chambless DL, Barber JP, et al: Treatment of anxiety and mood comorbidities in cognitive-behavioral and psychodynamic therapies for panic disorder. J Psychiatr Res 2019; 114:34–40
32.
Milrod B, Chambless DL, Gallop R, et al: Psychotherapies for panic disorder: a tale of two sites. J Clin Psychiatry 2016; 77:927–935
33.
Svensson M, Nilsson T, Perrin S, et al: The effect of patient’s choice of cognitive behavioural or psychodynamic therapy on outcomes for panic disorder: a doubly randomised controlled preference trial. Psychother Psychosom 2021; 90:107–118
34.
Cloitre M, Stolbach BC, Herman JL, et al: A developmental approach to complex PTSD: childhood and adult cumulative trauma as predictors of symptom complexity. J Trauma Stress 2009; 22:399–408
35.
Weathers FW, Bovin MJ, Lee DJ, et al: The Clinician-Administered PTSD Scale for DSM-5 (CAPS-5): development and initial psychometric evaluation in military veterans. Psychol Assess 2018; 30:383–395
36.
Hamilton M: A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23:56–62
37.
First MB: Structured Clinical Interview for the DSM (SCID); in The Encyclopedia of Clinical Psychology. Edited by Cautin RL, Lilienfeld SO. Chichester, UK, Wiley, 2015
38.
Stovall-McClough KC, Cloitre M: Unresolved attachment, PTSD, and dissociation in women with childhood abuse histories. J Consult Clin Psychol 2006; 74:219–228
39.
Ensink K, Berthelot N, Bernazzani O, et al: Another step closer to measuring the ghosts in the nursery: preliminary validation of the Trauma Reflective Functioning Scale. Front Psychol 2014; 5:1471
40.
Frewen PA, Dozois DJA, Neufeld RWJ, et al: Meta-analysis of alexithymia in posttraumatic stress disorder. J Trauma Stress 2008; 21:243–246
41.
Wittmann L, Halpern J, Adams CBL, et al: Prolonged exposure and psychodynamic treatment for posttraumatic stress disorder (letter). J Am Acad Child Adolesc Psychiatry 2011; 50:521–522
42.
APA Guidelines for Psychological Practice With Sexual Minority Persons. Washington, DC, American Psychological Association, 2021
43.
Markowitz JC, Petkova E, Neria Y, et al: Is exposure necessary? A randomized clinical trial of interpersonal psychotherapy for PTSD. Am J Psychiatry 2015; 172:430–440
44.
Bondjers K, Hyland P, Roberts NP, et al: Validation of a clinician-administered diagnostic measure of ICD-11 PTSD and complex PTSD: the International Trauma Interview in a Swedish sample. Eur J Psychotraumatol 2019; 10:1665617
45.
Hamilton M: The assessment of anxiety states by rating. Br J Med Psychol 1959; 32:50–55
46.
Porter E, Chambless DL, McCarthy KS, et al: Psychometric properties of the reconstructed Hamilton Depression and Anxiety Scales. J Nerv Ment Dis 2017; 205:656–664
47.
Leon AC, Shear MK, Portera L, et al: Assessing impairment in patients with panic disorder: the Sheehan Disability Scale. Soc Psychiatry Psychiatr Epidemiol 1992; 27:78–82
48.
Bates D, Mächler M, Bolker B, et al: Fitting linear mixed-effects models using lme4. J Stat Softw 2015; 67:1–48
49.
Kuznetsova A, Brockhoff PB, Christensen RHB: lmerTest package: tests in linear mixed effects models. J Stat Softw 2017; 82:1–26
50.
Foa EB, McLean CP, Zang Y, et al: Effect of prolonged exposure therapy delivered over 2 weeks vs 8 weeks vs present-centered therapy on PTSD symptom severity in military personnel: a randomized clinical trial. JAMA 2018; 319:354–364
51.
Mitchell S, Mitchell R, Shannon C, et al: Effects of baseline psychological symptom severity on dropout from trauma-focused cognitive behavior therapy for posttraumatic stress disorder: a meta-analysis. Traumatology (Epub 2022). doi:
52.
Soto A, Smith TB, Griner D, et al: Cultural adaptations and therapist multicultural competence: two meta-analytic reviews. J Clin Psychol 2018; 74:1907–1923
53.
Milrod B, Keefe JR, Choo T-H, et al: Separation anxiety in PTSD: a pilot study of mechanisms in patients undergoing IPT. Depress Anxiety 2020; 37:386–395
54.
Bailey HN, Moran G, Pederson DR: Childhood maltreatment, complex trauma symptoms, and unresolved attachment in an at-risk sample of adolescent mothers. Attach Hum Dev 2007; 9:139–161
55.
Markowitz JC, Neria Y, Lovell K, et al: History of sexual trauma moderates psychotherapy outcome for posttraumatic stress disorder. Depress Anxiety 2017; 34:692–700
56.
Chaimani A, Salanti G: Using network meta-analysis to evaluate the existence of small-study effects in a network of interventions. Res Synth Methods 2012; 3:161–176
57.
Keefe JR, Solomonov N, Derubeis RJ, et al: Focus is key: panic-focused interpretations are associated with symptomatic improvement in panic-focused psychodynamic psychotherapy. Psychother Res 2019; 29:1033–1044
58.
Keefe JR, Huque ZM, DeRubeis RJ, et al: In-session emotional expression predicts symptomatic and panic-specific reflective functioning improvements in panic-focused psychodynamic psychotherapy. Psychotherapy 2019; 56:514–525
59.
Barber JP, Milrod B, Gallop R, et al: Processes of therapeutic change: results from the Cornell-Penn Study of Psychotherapies for Panic Disorder. J Couns Psychol 2020; 67:222–231
60.
Dyar C, Sarno EL, Newcomb ME, et al: Longitudinal associations between minority stress, internalizing symptoms, and substance use among sexual and gender minority individuals assigned female at birth. J Consult Clin Psychol 2020; 88:389–401
Information & Authors
Information
Published In
History
Received: 1 May 2022
Revision received: 18 January 2023
Accepted: 27 January 2023
Published online: 19 May 2023
Published in print: September 01, 2023
Keywords
Authors
Competing Interests
Dr. Milrod is a coauthor of Trauma-Focused Psychodynamic Psychotherapy: A Step-by-Step Treatment Manual and receives royalties from Oxford University Press. The other authors report no financial relationships with commercial interests.
Funding Information
This study was funded by a 2020–2021 Dean’s Diversity and Healthcare Disparities grant from the Weill Cornell Medical College Dean’s Office and by a TL1 grant (NIH) from the Weill Cornell Clinical Translational Science Center (TL1-TR-002386 to Dr. Keefe).The content of this article is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; or decision to submit the manuscript for publication.
Metrics & Citations
Metrics
Citations
Export Citations
If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.
For more information or tips please see 'Downloading to a citation manager' in the Help menu.
View Options
View options
PDF/EPUB
View PDF/EPUBLogin options
Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.
Personal login Institutional Login Open Athens loginNot a subscriber?
PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.
Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).